| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/11/2010 | WO2010027770A1 Crystalline forms of sufentanil citrate |
| 03/11/2010 | WO2010027762A1 Indolizine inhibitors of leukotriene production |
| 03/11/2010 | WO2010027746A2 Hedgehog pathway modulators |
| 03/11/2010 | WO2010027641A2 Na channels, disease, and related assays and compositions |
| 03/11/2010 | WO2010027594A2 Cinnamic acid-based oligomers and uses thereof |
| 03/11/2010 | WO2010027572A2 Reducing cholesterol levels with combined use of querceting and statin |
| 03/11/2010 | WO2010027567A2 Tricyclic spirocycle derivatives and methods of use thereof |
| 03/11/2010 | WO2010027564A2 Amido anti-viral compounds, compositions, and methods of use |
| 03/11/2010 | WO2010027508A1 Methods for diagnosis or treatment of amyloidosis by targeting hyper-sulfated proteoglycans present in amyloid |
| 03/11/2010 | WO2010027502A2 Method of inducing an anti-viral immune response |
| 03/11/2010 | WO2010027500A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 03/11/2010 | WO2010027498A2 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
| 03/11/2010 | WO2010027496A1 Triazole antifungal agents |
| 03/11/2010 | WO2010027458A2 Pdk inhibitor compounds and methods of use thereof |
| 03/11/2010 | WO2010027448A1 Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists |
| 03/11/2010 | WO2010027433A2 Sn-2 myristate-containing edible oil |
| 03/11/2010 | WO2010027431A1 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| 03/11/2010 | WO2010027428A1 Platinum ( iv) complexes for use in dual mode pharmaceutical therapy |
| 03/11/2010 | WO2010027424A2 9-substituted phenanthrene based tylophorine derivatives |
| 03/11/2010 | WO2010027340A1 Pharmaceutical compositions composing entakapon, levodopa and karbidoba |
| 03/11/2010 | WO2010027294A1 Composition for treating dysplastic changes in the uterine cervix |
| 03/11/2010 | WO2010027280A1 Nitrobenzindoles and their use in cancer therapy |
| 03/11/2010 | WO2010027266A1 Means and methods for counteracting neurological disorders |
| 03/11/2010 | WO2010027189A2 A new use for homoisoflavanone or a salt thereof |
| 03/11/2010 | WO2010027114A1 Use of pyrazole-pyridine derivatives and its salts for treating or reventin osteoporosis |
| 03/11/2010 | WO2010027101A1 Solid preparation for medical use |
| 03/11/2010 | WO2010027097A1 Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| 03/11/2010 | WO2010027094A1 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM |
| 03/11/2010 | WO2010027040A1 HAIR GROWTH PROMOTING AGENT CONTAINING 15,15-DIFLUOROPROSTAGLANDIN F2α DERIVATIVE AS ACTIVE INGREDIENT |
| 03/11/2010 | WO2010027028A1 Agent for ameliorating impaired brain function |
| 03/11/2010 | WO2010027014A1 Method for improving absorption of s-adenosyl-l-methionine, and composition having improved s-adenosyl-l-methionine absorption |
| 03/11/2010 | WO2010027010A1 Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| 03/11/2010 | WO2010027005A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| 03/11/2010 | WO2010027002A1 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 03/11/2010 | WO2010026993A1 Method for improving absorbability of preparation, and preparation having improved absorbability |
| 03/11/2010 | WO2010026966A1 Novel anti-hcv agent and use thereof |
| 03/11/2010 | WO2010026873A1 Novel compound ceramidastin, process for production thereof, and use thereof |
| 03/11/2010 | WO2010026766A1 Agent for treating myelofibrosis |
| 03/11/2010 | WO2010026760A1 Compositions wherein bioactive components are stably sealed |
| 03/11/2010 | WO2010026711A1 Platinum complex and medical compound containing same |
| 03/11/2010 | WO2010026701A1 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient |
| 03/11/2010 | WO2010026660A1 Rna capable of inhibiting expression of zfat gene |
| 03/11/2010 | WO2010026652A2 Safe tooth extraction method and method of cleaning and sterilizing oral organs using neutralization reaction between sterilized water and aqueous antioxidant solution |
| 03/11/2010 | WO2010026602A2 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis |
| 03/11/2010 | WO2010026597A1 Oral dosage forms of linezolid and processes for their preparation |
| 03/11/2010 | WO2010026596A2 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses |
| 03/11/2010 | WO2010026592A1 Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis |
| 03/11/2010 | WO2010026545A1 Manganese and cobalt complexes, their preparation and use |
| 03/11/2010 | WO2010026526A1 Combination therapy for tuberculosis |
| 03/11/2010 | WO2010026487A1 Therapeutic methods and compositions |
| 03/11/2010 | WO2010026470A1 Stable dosage forms of antihypertensive agents |
| 03/11/2010 | WO2010026469A1 Pharmaceutical composition for use in treating sexually transmitted infections |
| 03/11/2010 | WO2010026467A2 Controlled release dosage form of high solubility active ingredient |
| 03/11/2010 | WO2010026436A2 Pharmaceutical compounds |
| 03/11/2010 | WO2010026435A1 Use of 3,11b-cis-dihydrobenazine in the treatment of dementia and associated cognitive deficit |
| 03/11/2010 | WO2010026434A1 Dihydrotetrabenazine for treatment of asthma |
| 03/11/2010 | WO2010026388A1 Isatin derivatives for use as in vivo imaging agents |
| 03/11/2010 | WO2010026375A1 Pharmaceutical preparation comprising a catechin |
| 03/11/2010 | WO2010026325A1 Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, n-palmitoyl isoleucine, and n-cocoyl alanine as an active agent controlling the proportion of basal keratinocytes of the human skin epidermis and expressing the nuclear form of surviving, and anti-aging cosmetic composition comprising same |
| 03/11/2010 | WO2010026276A1 Use of rapamycin and derivatives for the treatment of african trypanosomiasis |
| 03/11/2010 | WO2010026262A1 Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors |
| 03/11/2010 | WO2010026255A1 Process for preparing olmesartan medoxomil intermediate |
| 03/11/2010 | WO2010026238A1 Combination preparation for treating cancer |
| 03/11/2010 | WO2010026214A1 Pyrazolopyrimidines and their use for the treatment of cns disorders |
| 03/11/2010 | WO2010026212A1 Novel inhibitors |
| 03/11/2010 | WO2010026209A1 Use of isoQC inhibitors |
| 03/11/2010 | WO2010026208A1 1-aza-bicyclo[3.3.1]nonane or -3-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/11/2010 | WO2010026177A1 1,4-diaza-bicyclo [3.2.2] nonyl pyridine derivatives as nicotinic and monoamine receptor modulators |
| 03/11/2010 | WO2010026176A1 1,4 -diaza- bicyclo [3.2.2]n0nyl pyrimidine derivatives as nicotinic and monoamine receptor modulators |
| 03/11/2010 | WO2010026154A1 A method for combating adverse effects arising from antipsychotic treatment |
| 03/11/2010 | WO2010026153A1 Nucleoside derivatives as inhibitors of viral polymerases |
| 03/11/2010 | WO2010026134A1 Triazole derivatives and their use as nicotinic acetylcholine receptor modulators |
| 03/11/2010 | WO2010026129A1 The trpvl antagonist sb-705498 for treating rhinitis |
| 03/11/2010 | WO2010026128A1 N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis |
| 03/11/2010 | WO2010026124A1 Picolinamide derivatives as kinase inhibitors |
| 03/11/2010 | WO2010026122A1 Heterocyclic pim-kinase inhibitors |
| 03/11/2010 | WO2010026121A1 Bicyclic kinase inhibitors |
| 03/11/2010 | WO2010026113A1 Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
| 03/11/2010 | WO2010026112A1 5-substituted benzoxazines |
| 03/11/2010 | WO2010026104A1 4-tetrahydropyran-aminopyridine derivatives and their medical use |
| 03/11/2010 | WO2010026096A1 7-(piperazine-1-ymethyl)-1h-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 map kinase inhibitors for the treatment of respiratory diseases |
| 03/11/2010 | WO2010026095A1 Novel benzamides, production thereof, and use thereof as medicaments |
| 03/11/2010 | WO2010026094A1 Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8 |
| 03/11/2010 | WO2010026087A1 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| 03/11/2010 | WO2010026075A1 Pyridine derivatives as inhibitors of hiv-i reverse transcriptase |
| 03/11/2010 | WO2010026029A1 Use of quinazoline derivatives for the treatment of viral diseases |
| 03/11/2010 | WO2010025934A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid |
| 03/11/2010 | WO2010025931A2 Pharmaceutical combination |
| 03/11/2010 | WO2010025930A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol |
| 03/11/2010 | WO2010025890A1 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| 03/11/2010 | WO2010025872A2 Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl |
| 03/11/2010 | WO2010025856A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| 03/11/2010 | WO2010025848A1 Particles made of ziprasidone and a pharmaceutical composition containing disintegrant |
| 03/11/2010 | WO2010025821A1 Monoterpenes for treating respiratory tract diseases, in particular bronchopulmonary diseases |
| 03/11/2010 | WO2010025632A1 A methods for preparing the clathrate compound of steroid medicines utilizing hydrotalcite as carrier |
| 03/11/2010 | WO2010025631A1 A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid |
| 03/11/2010 | WO2010025630A1 Sodium cholate-included prednisone intercalated layered double hydroxides and preparation method thereof |
| 03/11/2010 | WO2010025589A1 Long acting curcumine derivates and preparation method thereof |
| 03/11/2010 | WO2010025558A1 Triazolium and imidazolium salts and uses thereof as antimalarials |
| 03/11/2010 | WO2010025555A1 Periostin-induced pancreatic regeneration |